He adds that the company plans to make BK Medical's technologies available on GE's Edison platform, which incorporates existing workflows and applications to integrate and assimilate data from disparate sources, as well as leverage analytics and advanced algorithms to generate clinical, operational, and financial insights. "That not only gives advantages on the workflow side to connect these devices or data flows better, but we can add AI capabilities, which we have implemented in our other modalities," said Rott.

GE Healthcare recently unveiled a new point-of-care ultrasound system to its portfolio back in March, Venue Fit, which is designed to fit into tight spaces and provide quick insights. For its Venue Go and Venue ultrasound systems, it also launched an industry-first AI tool for cardiac scanning, RealTime EF, which continuously calculates the heart’s real-time ejection fraction during live scanning with an integrated quality indicator.

Just last month, the company struck a deal with Koios Medical that will see the integration of Koios’ DS Breast AI technology on GE’s Invenia ABUS 2.0 automated whole breast ultrasound scanning system for early breast cancer detection. The system is the only FDA-approved ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue.

The deal with BK Medical is expected to close in 2022 and is subject to review by relevant regulatory authorities.

Back to HCB News

Business Affairs Homepage